Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Trial Profile

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms ASPC
  • Most Recent Events

    • 18 Sep 2018 Planned End Date changed from 1 Mar 2020 to 1 Aug 2020.
    • 18 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Mar 2020.
    • 16 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 15 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top